Zollinger‑Ellison Syndrome Stomach Pain
What is Zollinger‑Ellison syndrome stomach pain?
Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑producing tumors (gastrinomas) develop in the pancreas or duodenum. The excess gastrin stimulates the stomach lining to produce **large volumes of acid**, leading to ulcer formation and, consequently, chronic or severe stomach (epigastric) pain.
The pain associated with ZES is often described as a burning, gnawing, or cramping sensation that may improve after eating (because food buffers acid) or worsen after meals or at night. Because the disease is uncommon, many patients are initially misdiagnosed with more common peptic‑ulcer disease or gastro‑esophageal reflux disease (GERD).
Common Causes
While ZES itself is caused by gastrinomas, the stomach pain that patients experience can be mimicked or triggered by a number of other conditions. Recognizing these helps clinicians consider ZES in the differential diagnosis.
- Peptic ulcer disease (PUD) – H. pylori infection or NSAID use can create ulcers that cause similar epigastric pain.
- Gastro‑esophageal reflux disease (GERD) – Acid reflux can produce burning pain that radiates to the chest.
- Pancreatitis – Inflammation of the pancreas can refer pain to the stomach region.
- Gallbladder disease (cholelithiasis, cholecystitis) – Biliary colic may feel like upper‑abdominal pain.
- Functional dyspepsia – A disorder of gut–brain interaction that causes chronic indigestion without a clear structural cause.
- Gastroparesis – Delayed gastric emptying produces fullness, bloating, and epigastric discomfort.
- Small‑bowel bacterial overgrowth (SIBO) – Gas and acid production can lead to abdominal pain.
- Inflammatory bowel disease (Crohn’s disease involving the upper GI tract) – May cause ulceration and pain.
- Medication‑induced gastritis – Steroids, bisphosphonates, and certain antibiotics can irritate the stomach lining.
- Zollinger‑Ellison syndrome (gastrinoma) – The primary cause of excessive acid and hence the pain described in this article.
Associated Symptoms
Patients with ZES typically present with a constellation of gastrointestinal and systemic signs that result from relentless acid production.
- Recurrent or multiple duodenal and gastric ulcers (often >3 cm or in atypical locations)
- Acid‑related diarrhea or steatorrhea (fatty stools) – acid inactivates pancreatic enzymes.
- Unexplained weight loss despite normal or increased appetite.
- Frequent heartburn or GERD‑like symptoms.
- Nausea and occasional vomiting (sometimes with blood if an ulcer erodes).
- Abdominal bloating and early satiety.
- Rarely, gastric outlet obstruction** due to ulcer scarring.
- Signs of a **MEN‑1 syndrome** (parathyroid hyperplasia, pituitary tumors) when ZES occurs as part of this genetic condition.
When to See a Doctor
Because ZES can lead to serious complications, timely medical evaluation is essential. Seek professional care if you experience any of the following:
- Severe or persistent epigastric pain lasting more than a few weeks.
- Recurrent ulcers despite standard ulcer therapy (PPIs, H2 blockers).
- Unexplained chronic diarrhea, especially if oily or foul‑smelling.
- Rapid, unexplained weight loss (>5 % of body weight in 6 months).
- Vomiting blood (hematemesis) or black, tarry stools (melena).
- Persistent heartburn that does not improve with over‑the‑counter antacids.
- Family history of multiple endocrine neoplasia type 1 (MEN‑1) or known gastrinomas.
Early evaluation can prevent complications such as perforated ulcers, severe bleeding, or metastatic cancer.
Diagnosis
Diagnosing ZES involves confirming **hypergastrinemia** and demonstrating **acid hypersecretion**, followed by localization of the tumor.
Laboratory Tests
- Fasting serum gastrin level: Values >1000 pg/mL are highly suggestive, especially when accompanied by low gastric pH. Values between 100–1000 pg/mL require further testing.
- Secretin stimulation test: In ZES, gastrin paradoxically rises after IV secretin administration; a rise >120 pg/mL is diagnostic.
- Gastric pH measurement: A pH <2 confirms acid hypersecretion.
- Basic metabolic panel, CBC, and liver function tests to assess overall health and look for anemia from bleeding.
Imaging Studies
- Endoscopic ultrasound (EUS): Highly sensitive for small pancreatic or duodenal gastrinomas.
- Multiphasic contrast‑enhanced CT or MRI: Detects larger primary tumors and metastatic spread, especially to the liver.
- Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT: Identifies tumors that express somatostatin receptors, improving localization.
- Upper endoscopy (EGD): Visualizes ulcers and can obtain biopsies to rule out malignancy.
Histology
If a lesion is resected, pathology confirms neuroendocrine tumor (NET) features – uniform cells, “salt‑and‑pepper” chromatin, and positive immunostaining for gastrin.
Treatment Options
Therapy aims to (1) control acid production, (2) remove or control the gastrinoma, and (3) manage complications.
Medical Management
- High‑dose proton pump inhibitors (PPIs): Omeprazole 40–80 mg daily or equivalent is first‑line; they reduce acid output and heal ulcers.
- H2‑receptor antagonists: May be added for breakthrough symptoms, though PPIs are superior.
- Antidiarrheal agents: Loperamide for symptomatic control of acid‑induced diarrhea.
- Somatostatin analogs (octreotide, lanreotide): Decrease gastrin secretion and can shrink tumor burden, especially in metastatic disease.
- Chemotherapy or targeted therapy: For unresectable metastatic NETs (e.g., everolimus, sunitinib) based on oncologic evaluation.
- Nutritional support: Small, frequent meals; low‑fat diet to reduce steatorrhea; supplementation of fat‑soluble vitamins if malabsorption persists.
Surgical Options
- Enucleation or local resection: Preferred for solitary, small (<2 cm) gastrinomas without metastasis.
- Pancreaticoduodenectomy (Whipple procedure): Considered for larger tumors in the pancreatic head or when adjacent structures are involved.
- Hepatic metastasectomy: Removal of liver metastases can improve survival in selected patients.
- Debulking surgery: Reduces tumor mass when complete resection is impossible, often combined with medical therapy.
Follow‑up Care
After initial treatment, patients need lifelong surveillance:
- Annual fasting gastrin level and gastric pH check.
- Periodic imaging (CT/MRI or somatostatin receptor PET) every 6–12 months to monitor recurrence.
- Endoscopic evaluation every 1–2 years to assess ulcer healing.
Prevention Tips
Because ZES is caused by a neuroendocrine tumor, primary prevention is not possible for most individuals. However, patients can reduce complications and support overall gastrointestinal health with the following measures:
- Adhere strictly to prescribed high‑dose PPI regimen; never stop abruptly without physician guidance.
- Avoid NSAIDs, aspirin, and other ulcer‑causing medications unless specifically prescribed.
- Limit alcohol and quit smoking – both worsen ulcer disease and may influence tumor progression.
- Eat small, low‑fat meals spaced throughout the day to minimize acid stimulus.
- Maintain a healthy weight and engage in regular exercise; obesity can increase gastro‑intestinal reflux.
- If you have MEN‑1 or a family history of gastrinomas, undergo regular screening per endocrinology recommendations.
- Stay up‑to‑date with vaccinations (e.g., hepatitis B) as some treatments (e.g., chemotherapy) may suppress immunity.
Emergency Warning Signs
- Sudden, severe abdominal pain with a rigid or board‑like abdomen (possible perforated ulcer).
- Vomiting blood or material that looks like coffee grounds.
- Black, tarry stools indicating upper‑GI bleeding.
- Rapid heart rate, low blood pressure, or fainting—signs of significant blood loss.
- High‑fever (>38.5 °C) with worsening abdominal pain (possible infection or perforation).
- Acute worsening of diarrhea leading to dehydration (dry mouth, dizziness, decreased urine output).
If any of these occur, call emergency services (911) or go to the nearest emergency department immediately.
References
- Mayo Clinic. “Zollinger‑Ellison syndrome.” Updated 2023. https://www.mayoclinic.org
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Zollinger‑Ellison Syndrome.” 2022. https://www.niddk.nih.gov
- Cleveland Clinic. “Gastrinoma (Zollinger‑Ellison Syndrome).” 2023. https://my.clevelandclinic.org
- World Health Organization. “Neuroendocrine Tumors.” WHO Classification of Tumours, 5th Edition, 2024.
- Feldman M, et al. “Management of Zollinger‑Ellison Syndrome.” *Gastroenterology* 2021;160(4):1235‑1247.